Figure 2From: Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study Percentage of a) clinical responders and b) symptomatic remitters. Note: Clinical response was defined as a change in ADHD-RS-IV total score of ≥30% from baseline and a CGI-I score of 1 or 2. Symptomatic Remission was defined as a post baseline ADHD-RS-IV total score of ≤18.Back to article page